BridgeBio partners with biomanufacturer Resilience to produce early-stage AAV gene therapies

BridgeBio has tapped biomanufacturing company National Resilience to produce two of its early-phase adeno-associated virus (AAV) gene therapies in a partnership designed to run beyond clinical trials.

Resilience is tasked to manufacture AAV5 gene therapy BBP-631 for congenital adrenal hyperplasia and AAV9 gene therapy BBP-812 for Canavan disease. BBP-631 is in a 25-patient Phase I/II trial, with early data expected before the end of the year. Meanwhile, BBP-812 is in an 18-patient Phase I/II study, with results likely to be unveiled next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Adolescents’ genetic risks tied to psychotic symptoms

Researchers examine the relationships between neuropsychiatric and cognitive polygenic scores, attention-related phenotypes, and psychosis symptoms.

November 1, 2024

Biden to Visit Site of Toxic Norfolk Southern Train Derailment

President Biden will travel to East Palestine, Ohio, the site of a train derailment and hazardous chemical spill, this month for a meeting with residents,

February 2, 2024

Fauci’s West Nile Virus; Nobel Prize for miRNA; Nurse Dies in Hurricane Flood

Note that some links may require registration or subscription. Anthony Fauci, MD, the former director of the National Institute of Allergy and Infectious Diseases (NIAID),

October 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.